Roche: results of study for Covid-19 patients
(CercleFinance.com) - Roche says the phase III EMPACTA study showed that Actemra/RoActemra reduced the likelihood of requiring mechanical ventilation in hospitalised patients suffering from COVID-19-associated pneumonia.
EMPACTA is the first global phase III trial to demonstrate the efficacy of Actemra/RoActemra in COVID-19-associated pneumonia.
Patients are 44% less likely to have to go on ventilators or die than patients who received a placebo.
The group said that it intends to share this important data with the FDA and other health authorities worldwide.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
EMPACTA is the first global phase III trial to demonstrate the efficacy of Actemra/RoActemra in COVID-19-associated pneumonia.
Patients are 44% less likely to have to go on ventilators or die than patients who received a placebo.
The group said that it intends to share this important data with the FDA and other health authorities worldwide.
Copyright (c) 2020 CercleFinance.com. All rights reserved.